Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 July 2022 | Story Andre Damons | Photo Supplied
Prof Martie Smith and Prof Drik Opperman
Prof Martie Smit and Prof Dirk Opperman in the Department of Microbiology and Biochemistry filed a patent entitled “Process for the chemical modification of alkanes, fatty acids and fatty alcohols”.

Flavours and fragrances have a wide application in the food, feed, cosmetic, chemical and pharmaceutical sectors. Many flavour compounds are still produced via chemical synthesis or via extraction from plant or animal sources. However, there is increasing interest in their bio-production or the use of flavour compounds of (micro) biological origin. 

One reason for this shift is that chemical synthesis often uses environmentally unfriendly processes. Chemical synthesis usually also produces racemic mixtures with the second enantiomer, mirror image of the looked-for compound, often having undesirable organoleptic properties. Furthermore, the consumer has developed a “chemophobia”-attitude towards synthetic chemical compounds, especially when related to food and home-care products.  This applies even to nature-identical compounds – products that occur in nature but are produced via a non-natural chemical process. Products produced with the use of enzymes or microbes from “natural” substrates can be labelled “natural”. The flavour and fragrance industry thus pay higher prices for such products labelled as “natural”.  

The invention

A University of the Free State (UFS) team, led by Prof Martie Smit and Prof Dirk Opperman in the Department of Microbiology and Biochemistry are conducting exciting research in this area. They filed a patent entitled “Process for the chemical modification of alkanes, fatty acids and fatty alcohols”.  

The invention relates to a process for the enzymatic in-chain hydroxylation of C12 to C16 fatty acids, alcohols, and alkanes. Hydroxylation of C12 fatty acid and alcohol provides routes for the synthesis of “natural” δ-dodecalactone. The advantage of these routes is that they do not rely on massoia lactones. Massoia lactones are derived from the bark of Massoia trees which grow in Indonesia. Harvesting of the bark kills the trees.  

The cytochrome P450 enzymes (P450s) claimed in this patent are to the inventors’ knowledge the most regioselective enzymes described thus far that can be used for the synthesis of δ-dodecalactone from lauric acid or 1-dodecanol. The approach that the technology takes is to claim cytochrome P450 enzymes that share 70 % amino acid identity to a set of selected P450s for the regioselective hydroxylation of lauric acid and 1-dodecanol to synthesise δ-dodecalactone.

Still in early stage

The current state of development is early stage with the technology only demonstrated in the laboratory on a small scale (100-200 ml). Before the technology can be commercialised the team would need to further improve the regioselectivity and stability of the P450s and proof that the reactions can be scaled up in bioreactors. The technology will probably be delivered as an enzyme (amino acid sequence) with the desired properties. 

There are other research groups working on a synthetic biology approach for the de novo synthesis of δ-dodecalactone from glucose by genetically engineered microbes. It is still unclear how such a process will compare in terms of product yields, economics and environmental impact with the processes proposed by the UFS patent.

If the team had to partner with a commercial company, their first choice would be to work with an established flavour and fragrance company. Another possibility would be the small French flavour and fragrance company that Dr Alizé Pennec, the post-doc and co-inventor who initially discovered the unique P450 activity, is working for.

Please view the videos for more information on patents.

The Vice-Rector: Research and Internationalisation has released two new calls for applications for funding. Academic staff and researchers are encouraged to submit applications for these funds. At this stage we are not accepting projects from Research Fellows. 

The two funds are: 

1.  The Industrial Engagement Fund 
2.  The Intellectual Property Commercialisation Fund

Each fund has its own guidelines and application process. The guidelines are attached. The applications must be filled in on RIMS.

The RIMS application forms can be found through this link

For more information please click the documents below:



News Archive

Great turnout for Hannes Meyer Symposium in Cardiothoracic Surgery
2017-05-05

Description: Hannes Meyer Symposium  Tags: Hannes Meyer Symposium

Symposium attendees watch attentively as
Dr Johan Brink demonstrated a MAZE procedure
with a pig’s heart.
Photo: Supplied

The University of the Free State’s Faculty of Health Sciences hosted the annual Hannes Meyer Symposium in Cardiothoracic Surgery. The symposium was organised by Prof Francis Smit, head of the department of Cardiothoracic Surgery at the UFS, with the support from the Society of Cardiothoracic Surgeons of South Africa and the European Association of Cardiothoracic Surgery (EACTS). Over the past 16 years this symposium has steadily been growing in stature and prestige leading to the resounding success that was this year’s event.

Medical advancements explored
The aim of the symposium is to provide an overview of the latest advances in Cardiothoracic Surgery and perfusion as well as providing hands-on training via simulation to trainees from South Africa and the rest of the African continent. Didactic lectures and papers by registrars were an integral component of the symposium. The South African community was represented by various heads of departments, trainees, senior specialists and perfusionists from all the training centres in the country. There were also delegates representing Uganda, Mozambique, Nigeria and Zambia.

Heart surgery off to new heights
Simulation in Cardiothoracic Surgery and Perfusion can be compared to airline pilots with high risk, with complex surgeries being first done in simulators before being attempted in the real world. The UFS is proud to have a state-of-the-art simulation facility, which was used to facilitate the programme.

The range of simulation was extensive and included simple procedural models to complex full theatre setups with Human Performance Models in perfusion that simulated crisis scenarios with the aid of computerised devices that react in real time to human intervention.

Industry support highly appreciated
This event was coordinated by Dr Jehron Pillay, senior registrar in the Department of Cardiothoracic Surgery and Marilee Janse van Vuuren, deputy-director clinical technology, in the department. This was the first time that such extensive simulation models were used in the programme and judging from the positive response received, it has certainly set the benchmark for all future events.

The event has received invaluable support over the years from EACTS that has selected Bloemfontein as the site of its African training programme as a result of the high level of training and education achieved here.

The academic discussions were chaired by Profs Marko Turina and Jose Pomar (past presidents of EACTS) and Pieter Kappetein (past secretary general of EACTS) who are extremely well known internationally for their contribution to advancing Cardiothoracic training and education.

Our guests from EACTS presented didactical lectures on research methodology, international randomised trials and discussed recent developments and controversies in cardiothoracic surgery.

Registrars from all South African units presented a thoracic and cardiac surgery paper from each unit highlighting specific disease conditions, moderated by heads of departments and the international panel.

An event of this magnitude requires significant financial support and the medical industry in South Africa stepped up to the plate in providing financial and logistical support in order to make it possible.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept